InnoCan Pharma's Rebrand Vote Arrives as Skincare Arm Crosses 100,000 Reviews
Published on 08/09/2026 at 06:43 | Redaktion boerse-global.de
The countdown to InnoCan Pharma's shareholder meeting has begun, and the numbers coming out of its consumer business are doing some of the talking. With the August 17 vote on a corporate rebrand to "Velsa Corp" looming, the company is leaning on a skincare franchise that just notched its latest commercial milestone.
Valitic, the skin-care label housed under majority-owned B.I. Sky Global, has now accumulated more than 100,000 verified customer reviews across major US online marketplaces. The achievement, reported in early August, follows hot on the heels of the brand crossing the two-million-customer threshold in July. Management frames the review volume as validation of a data-driven marketing playbook — and, more importantly, as evidence that the wellness segment can function as the group's cash engine.
That engine has a specific job: fund InnoCan's pharmaceutical research without forcing the company back to the capital markets. The strategy hinges on the LPT-CBD liposome platform, the group's core technology for future drug applications, which recently received an INAD number from the FDA's veterinary medicine division. The designation is a formal prerequisite for advancing new animal drugs through the US approval process, and InnoCan also secured a sponsor fee waiver for 2026 — the third consecutive year the agency has granted that regulatory support.
A Quarter With Two Stories
The first-quarter 2026 results illustrate both the strengths and the strains of the dual-business model. Group revenue came in at $6.465 million for the three months through March, up 29.7% sequentially. The improvement was driven by cost reductions and fatter gross margins in the wellness segment, which helped contain net losses.
Managing risk is a discipline every business faces — whether it's pharmaceutical research or day-to-day operations. Many employers underestimate the dangerous gaps in their workplace safety documentation, leaving themselves exposed if something goes wrong. A free toolkit with 41 ready-to-use templates and checklists helps you document risks properly and stay compliant. Download the free Risk Assessment Toolkit
The year-over-year comparison, however, tells a more sobering story. Revenue fell 17.07% from the $7.796 million posted in the first quarter of 2025. Gross margin remained elevated at 91.1%, and the balance sheet showed a liquidity ratio of 3.72. Management has also shelved its planned US listing for now, choosing instead to direct resources toward growth in existing markets.
Shareholders Face Two Key Dates
For investors wanting a say in the company's future identity, the calendar is tightening. The deadline for submitting proxy votes on the rebrand is August 13 at 10:00 a.m. Eastern Time. Only shareholders registered in the company's books as of July 13 are eligible to vote. The formal ballot takes place at the annual general meeting on August 17, where the proposed name change to Velsa Corp will be put to a vote — a move designed to create a unified identity across the group's biotech and healthcare divisions.
A Volatile Stretch on the Hamburg Exchange
The stock's recent behavior suggests investors are keeping their powder dry. InnoCan shares closed at €1.50 in Hamburg on Friday, August 7, a 1.69% gain from the prior session's €1.475 close. But that modest uptick masks a choppy week in which the stock at times fell as much as 9% intraday. The swings come amid broader questions about whether InnoCan can sustain its pharma pipeline from internal resources alone.
Just as InnoCan is betting its future on a single high-stakes platform, your business faces its own critical compliance questions. What happens if a workplace accident occurs and your risk assessment is missing? Over 37,000 UK companies trust a free toolkit that provides 41 checklists and templates to protect their teams and their bottom line. Get the free Risk Assessment Toolkit
The longer-term chart shows just how far the equity has traveled. In October 2025, the shares touched a high of €12.48; by June 2026, they had slid to a low of €1.335. Market observers read the current level as investor caution ahead of the upcoming corporate decisions.
The August 17 meeting now shapes up as a defining moment. If shareholders approve the rebrand, Velsa Corp will emerge as the banner under which the company pursues its twin ambitions — pharmaceutical research funded by wellness cash flow. Whether those high-margin consumer revenues can close the gap to human clinical trials remains the central question for the months ahead.
